3 Penny Stocks Paying 18% to 23%: Why the Forward Yield Tells a Different Story

Articles about penny stocks with positive earnings and fat shareholder returns usually lead with the headline yield. That's understandable. A 20% distribution rate on a sub-$5 stock looks like you've found the machine the rest of the market forgot. But the TTM yield is the last chapter of the story, not the current one. Forward yields, NAV trends, and the structural mechanics of how these vehicles return cash tell a sharper picture.

All three names that fit this screen — profitable, under $5, paying dividends — are Business Development Companies. BDCs are closed-end lending vehicles regulated under the Investment Company Act of 1940. To avoid corporate income tax, they must distribute at least 90% of taxable income to shareholders. That structure guarantees the "shareholder returns" part of the premise. It also means the dividend is a plumbing requirement, not a discretionary signal of management confidence. When the income pool shrinks, the distribution has to follow.

The question isn't whether these stocks pay. It's whether they can keep doing so at a rate that compensates for the risk, and whether the current price already prices in deterioration.

1. Horizon Technology Finance (HRZN) — $4.64

HRZN lends to venture-backed companies in technology, life sciences, and cleantech. After completing its merger with Monroe Capital Corporation in April 2026, it runs a $696 million investment portfolio yielding 15.2% across its debt positions. The company generated $0.19 of net investment income per share in Q1 2026 and declared total distributions of $0.27 for the second quarter — which includes $0.09 of special "spillover" income that isn't recurring. The TTM yield of 18.5% is built on those elevated payouts. Strip out the specials, and the forward yield falls to 9.5%.

NAV per share stands at $6.98, well above the $4.64 trading price. The stock trades at 0.75x book value. On the surface, a 34% discount to NAV looks like margin of safety. But NAV can decline, and it did: Q1 2026 showed a net decrease in NAV of $0.06 per share from unrealized depreciation and realized losses on the portfolio. Revenue growth is flat-to-negative at -1.1% year over year. Free cash flow margin sits at 29%, which is healthy, but free cash flow in a BDC is largely the undistributed portion of lending income, not expansion.

HRZN has paid distributions for 15 consecutive years. The current portfolio yield of 15.2% provides cover for the $0.72 annualized run rate of regular dividends, even at the reduced $0.06-per-month level. But the gap between TTM yield (18.5%) and forward yield (9.5%) means the income stream the headline promises is already being cut in half. The stock is down 28% year-to-date and 35% on a rolling 12-month basis. The market has already done the math.

Portfolio role: If you want venture-lending exposure at a steep discount to NAV, this is it. But it belongs in a satellite sleeve, not a core income holding. The trigger to reassess is NAV trajectory — two consecutive quarters of NAV decline would suggest portfolio credit deterioration beyond what the discount currently reflects.

2. Oxford Square Capital (OXSQ) — $1.49

OXSQ is the smallest of the three, with a $157 million market cap and a portfolio focused on syndicated bank loans and debt tranches of collateralized loan obligations. It has distributed to shareholders for 21 consecutive years, the longest track record in this group. The TTM yield is 23.3%, which is the highest of the three.

The factor stack behind that yield is deteriorating. Net investment income in Q2 2026 was $5.1 million, or $0.05 per share — down sharply from prior quarters. Revenue is declining 7.2% year over year and 14.1% quarter over quarter. Return on equity is negative at -26.6%. The stock trades at $1.49 against a NAV of $1.29, which means unlike HRZN, there is no meaningful discount to book. If anything, the price sits slightly above NAV.

The forward yield of 9.4% tells the real income story: the TTM yield was propped up by prior-year distributions that won't repeat at the same level. With income shrinking and the portfolio exposed to CLO mezzanine and equity tranches — which sit lower in the capital stack and bear the first losses if loan quality deteriorates — the combination of negative ROE and declining NII is a red flag for distribution sustainability.

OXSQ's stock is down 37% on a rolling annual basis and 15% year-to-date. At $1.49, it trades at just 4.3x trailing earnings, but those earnings are negative on a TTM basis (negative PE of -4.3), so the multiple is a mathematical artifact, not a valuation signal.

Portfolio role: Speculative income. The 21-year track record is impressive, but track records don't override current-quarter trends. This belongs only for investors who believe CLO spreads will widen enough to boost carry, and who accept that the distribution could be cut further. The trigger to exit is the next quarter where NII falls below $0.04 per share — that would be the threshold where covering even the reduced $0.035-per-month distribution becomes questionable.

3. Prospect Capital (PSEC) — $2.33

PSEC is the largest and most diversified of the three, with a $1.17 billion market cap. It has also distributed to shareholders for 21 consecutive years. The TTM yield is 21%, sitting between HRZN and OXSQ. But unlike the other two, PSEC generates genuinely strong operating cash flow: $553 million TTM, with an operating margin of 50.4% and EBITDA margin of 52.4%. Free cash flow margin is 85%.

The discount to NAV is the most striking number here. PSEC trades at 0.26x book value. NAV per share was $6.21 as of the December 2025 quarter. The stock at $2.33 represents a 63% discount — far steeper than HRZN's 34% gap or OXSQ's slight premium. The market is pricing in severe stress, and for good reason: revenue is down 14.9% year over year and 14.7% quarter over quarter. The forward yield of 7.7% is the lowest of the three, reflecting distribution reductions.

But the underlying business is still cash-generative. Debt-to-equity sits at 37.9%, which is conservative for a BDC. Return on equity is negative at -5.1%, but that reflects mark-to-market unrealized losses on the portfolio, not a fundamental inability to earn. Q1 2026 EPS was $0.16 per share. The company holds $553 million in trailing free cash flow against $1.73 billion in net debt — a coverage ratio of roughly 0.32x on an annualized basis, which means refinancing and debt management are the binding constraint.

PSEC is the one name in this group where the NAV discount creates real optionality. If the credit cycle stabilizes and the portfolio mark-to-market losses narrow, the path back toward even half of NAV implies substantial upside from here. The EV/EBITDA multiple of 8.5x is reasonable for a leveraged credit business, even a distressed one. The stock is up 9.4% over the past five trading days, suggesting some capitulation buying has begun.

Portfolio role: Deep value credit play. This is the highest-conviction asymmetric bet of the three, but it requires patience and tolerance for distribution cuts. The trigger to add is confirmation that revenue decline stabilizes (QoQ revenue flat or positive) combined with NAV holding steady. The trigger to cut is NAV falling below $5.50, which would suggest the portfolio impairment is more structural than cyclical.

What the factor stack says

These three names illustrate the core tension in penny-stock income investing. The TTM yield is a rearview mirror. Forward yield, NAV trajectory, and the structural relationship between book value and price are the inputs that matter.

Looking at them side by side:

• Forward yield rank: HRZN (9.5%) > OXSQ (9.4%) > PSEC (7.7%). The income the market can currently count on is roughly half of what the TTM yield suggests across all three.
• Discount to NAV rank: PSEC (0.26x book, 63% discount) > HRZN (0.75x book, 25% discount) > OXSQ (1.27x book, slight premium). PSEC offers the most margin of safety if NAV holds.
• Revenue trajectory: All three are declining. PSEC's decline (-14.9%) is the steepest, but it generates the most cash to absorb it. OXSQ's negative ROE of -26.6% is the most alarming.

The barbell interpretation is straightforward. HRZN offers the cleanest current income at a modest NAV discount, suitable for an income sleeve if you accept a ~9% yield rather than the headline 18%. PSEC offers asymmetric upside from a 63% NAV discount, but only if you can tolerate further distribution reductions and potential capital loss. OXSQ is the weakest of the three on fundamentals — the income is falling fastest, there's no NAV discount, and ROE is deeply negative. If you need three names, this is the one to skip.

What would change this view across the board? A sustained rally in high-yield credit spreads, which would boost the carry on existing loan portfolios and support both NAV and distribution levels. Conversely, a broad credit event that pushes default rates up through the leveraged-loan and venture-lending markets would compress distributions faster than any of these NAV discounts can absorb.